Search results for the GEO ID: GSE6960
(Click on the check boxes provided under "Select for analysis", to initiate grouping)
(Once the selection is made, click on "Add groups" in "Make groups for comparison", to make a group. Scroll down)
GSM ID
GPL ID
Select for analysis
Title
Source name
Description
Characteristics
GSM160468
GPL570
Control A non-cycling plateau phase A549 lung cancer cell culture A549 human lung cancer cells (1 x 10^5 cells per T-25 flask in 7 mL complete RPMI 1640 medium) were seeded 8 days prior to treatment of non-cycling plateau phase cultures with drug. At 4 hours prior to RNA isolation, control (5% mannitol) solution was added to the cultures. After incubation, cultures were washed twice with HBSS supplemented with 0.5% BSA and total RNA was isolated. A549 human lung cancer cells (1 x 10^5 cells per T-25 flask in 7 mL complete RPMI 1640 medium) were seeded 8 days prior to treatment of non-cycling plateau phase cultures with drug. At 4 hours prior to RNA isolation, control (5% mannitol) solution was added to the cultures. After incubation, cultures were washed twice with HBSS supplemented with 0.5% BSA and total RNA was isolated.
GSM160469
GPL570
Control B non-cycling plateau phase A549 lung cancer cell culture A549 human lung cancer cells (1 x 10^5 cells per T-25 flask in 7 mL complete RPMI 1640 medium) were seeded 8 days prior to treatment of non-cycling plateau phase cultures with drug. At 4 hours prior to RNA isolation, control (5% mannitol) solution was added to the cultures. After incubation, cultures were washed twice with HBSS supplemented with 0.5% BSA and total RNA was isolated. A549 human lung cancer cells (1 x 10^5 cells per T-25 flask in 7 mL complete RPMI 1640 medium) were seeded 8 days prior to treatment of non-cycling plateau phase cultures with drug. At 4 hours prior to RNA isolation, control (5% mannitol) solution was added to the cultures. After incubation, cultures were washed twice with HBSS supplemented with 0.5% BSA and total RNA was isolated.
GSM160470
GPL570
Control C non-cycling plateau phase A549 lung cancer cell culture A549 human lung cancer cells (1 x 10^5 cells per T-25 flask in 7 mL complete RPMI 1640 medium) were seeded 8 days prior to treatment of non-cycling plateau phase cultures with drug. At 4 hours prior to RNA isolation, control (5% mannitol) solution was added to the cultures. After incubation, cultures were washed twice with HBSS supplemented with 0.5% BSA and total RNA was isolated. A549 human lung cancer cells (1 x 10^5 cells per T-25 flask in 7 mL complete RPMI 1640 medium) were seeded 8 days prior to treatment of non-cycling plateau phase cultures with drug. At 4 hours prior to RNA isolation, control (5% mannitol) solution was added to the cultures. After incubation, cultures were washed twice with HBSS supplemented with 0.5% BSA and total RNA was isolated.
GSM160471
GPL570
Zinc A non-cycling plateau phase A549 lung cancer cell culture A549 human lung cancer cells (1 x 10^5 cells per T-25 flask in 7 mL complete RPMI 1640 medium) were seeded 8 days prior to treatment of non-cycling plateau phase cultures with drug. At 4 hours prior to RNA isolation, ZnOAc2 (25 μM final concentration) solution was added to the cultures. After incubation, cultures were washed twice with HBSS supplemented with 0.5% BSA and total RNA was isolated. A549 human lung cancer cells (1 x 10^5 cells per T-25 flask in 7 mL complete RPMI 1640 medium) were seeded 8 days prior to treatment of non-cycling plateau phase cultures with drug. At 4 hours prior to RNA isolation, ZnOAc2 (25 μM final concentration) solution was added to the cultures. After incubation, cultures were washed twice with HBSS supplemented with 0.5% BSA and total RNA was isolated.
GSM160472
GPL570
Zinc B non-cycling plateau phase A549 lung cancer cell culture A549 human lung cancer cells (1 x 10^5 cells per T-25 flask in 7 mL complete RPMI 1640 medium) were seeded 8 days prior to treatment of non-cycling plateau phase cultures with drug. At 4 hours prior to RNA isolation, ZnOAc2 (25 μM final concentration) solution was added to the cultures. After incubation, cultures were washed twice with HBSS supplemented with 0.5% BSA and total RNA was isolated. A549 human lung cancer cells (1 x 10^5 cells per T-25 flask in 7 mL complete RPMI 1640 medium) were seeded 8 days prior to treatment of non-cycling plateau phase cultures with drug. At 4 hours prior to RNA isolation, ZnOAc2 (25 μM final concentration) solution was added to the cultures. After incubation, cultures were washed twice with HBSS supplemented with 0.5% BSA and total RNA was isolated.
GSM160473
GPL570
Zinc C non-cycling plateau phase A549 lung cancer cell culture A549 human lung cancer cells (1 x 10^5 cells per T-25 flask in 7 mL complete RPMI 1640 medium) were seeded 8 days prior to treatment of non-cycling plateau phase cultures with drug. At 4 hours prior to RNA isolation, ZnOAc2 (25 μM final concentration) solution was added to the cultures. After incubation, cultures were washed twice with HBSS supplemented with 0.5% BSA and total RNA was isolated. A549 human lung cancer cells (1 x 10^5 cells per T-25 flask in 7 mL complete RPMI 1640 medium) were seeded 8 days prior to treatment of non-cycling plateau phase cultures with drug. At 4 hours prior to RNA isolation, ZnOAc2 (25 μM final concentration) solution was added to the cultures. After incubation, cultures were washed twice with HBSS supplemented with 0.5% BSA and total RNA was isolated.
GSM160474
GPL570
PCI 5002 A non-cycling plateau phase A549 lung cancer cell culture A549 human lung cancer cells (1 x 10^5 cells per T-25 flask in 7 mL complete RPMI 1640 medium) were seeded 8 days prior to treatment of non-cycling plateau phase cultures with drug. At 4 hours prior to RNA isolation, PCI-5002 (10 μM final concentration) solution was added to the cultures. After incubation, cultures were washed twice with HBSS supplemented with 0.5% BSA and total RNA was isolated. A549 human lung cancer cells (1 x 10^5 cells per T-25 flask in 7 mL complete RPMI 1640 medium) were seeded 8 days prior to treatment of non-cycling plateau phase cultures with drug. At 4 hours prior to RNA isolation, PCI-5002 (10 μM final concentration) solution was added to the cultures. After incubation, cultures were washed twice with HBSS supplemented with 0.5% BSA and total RNA was isolated.
GSM160475
GPL570
PCI 5002 B non-cycling plateau phase A549 lung cancer cell culture A549 human lung cancer cells (1 x 10^5 cells per T-25 flask in 7 mL complete RPMI 1640 medium) were seeded 8 days prior to treatment of non-cycling plateau phase cultures with drug. At 4 hours prior to RNA isolation, PCI-5002 (10 μM final concentration) solution was added to the cultures. After incubation, cultures were washed twice with HBSS supplemented with 0.5% BSA and total RNA was isolated. A549 human lung cancer cells (1 x 10^5 cells per T-25 flask in 7 mL complete RPMI 1640 medium) were seeded 8 days prior to treatment of non-cycling plateau phase cultures with drug. At 4 hours prior to RNA isolation, PCI-5002 (10 μM final concentration) solution was added to the cultures. After incubation, cultures were washed twice with HBSS supplemented with 0.5% BSA and total RNA was isolated.
GSM160476
GPL570
PCI 5002 C non-cycling plateau phase A549 lung cancer cell culture A549 human lung cancer cells (1 x 10^5 cells per T-25 flask in 7 mL complete RPMI 1640 medium) were seeded 8 days prior to treatment of non-cycling plateau phase cultures with drug. At 4 hours prior to RNA isolation, PCI-5002 (10 μM final concentration) solution was added to the cultures. After incubation, cultures were washed twice with HBSS supplemented with 0.5% BSA and total RNA was isolated. A549 human lung cancer cells (1 x 10^5 cells per T-25 flask in 7 mL complete RPMI 1640 medium) were seeded 8 days prior to treatment of non-cycling plateau phase cultures with drug. At 4 hours prior to RNA isolation, PCI-5002 (10 μM final concentration) solution was added to the cultures. After incubation, cultures were washed twice with HBSS supplemented with 0.5% BSA and total RNA was isolated.
GSM160477
GPL570
PCI 5002 Zinc A non-cycling plateau phase A549 lung cancer cell culture A549 human lung cancer cells (1 x 10^5 cells per T-25 flask in 7 mL complete RPMI 1640 medium) were seeded 8 days prior to treatment of non-cycling plateau phase cultures with drug. At 4 hours prior to RNA isolation, PCI-5002 (10 μM final concentration) + ZnOAc2 (25 μM final concentration) solution was added to the cultures. After incubation, cultures were washed twice with HBSS supplemented with 0.5% BSA and total RNA was isolated. A549 human lung cancer cells (1 x 10^5 cells per T-25 flask in 7 mL complete RPMI 1640 medium) were seeded 8 days prior to treatment of non-cycling plateau phase cultures with drug. At 4 hours prior to RNA isolation, PCI-5002 (10 μM final concentration) + ZnOAc2 (25 μM final concentration) solution was added to the cultures. After incubation, cultures were washed twice with HBSS supplemented with 0.5% BSA and total RNA was isolated.
GSM160478
GPL570
PCI 5002 Zinc B non-cycling plateau phase A549 lung cancer cell culture A549 human lung cancer cells (1 x 10^5 cells per T-25 flask in 7 mL complete RPMI 1640 medium) were seeded 8 days prior to treatment of non-cycling plateau phase cultures with drug. At 4 hours prior to RNA isolation, PCI-5002 (10 μM final concentration) + ZnOAc2 (25 μM final concentration) solution was added to the cultures. After incubation, cultures were washed twice with HBSS supplemented with 0.5% BSA and total RNA was isolated. A549 human lung cancer cells (1 x 10^5 cells per T-25 flask in 7 mL complete RPMI 1640 medium) were seeded 8 days prior to treatment of non-cycling plateau phase cultures with drug. At 4 hours prior to RNA isolation, PCI-5002 (10 μM final concentration) + ZnOAc2 (25 μM final concentration) solution was added to the cultures. After incubation, cultures were washed twice with HBSS supplemented with 0.5% BSA and total RNA was isolated.
GSM160479
GPL570
PCI 5002 Zinc C non-cycling plateau phase A549 lung cancer cell culture A549 human lung cancer cells (1 x 10^5 cells per T-25 flask in 7 mL complete RPMI 1640 medium) were seeded 8 days prior to treatment of non-cycling plateau phase cultures with drug. At 4 hours prior to RNA isolation, PCI-5002 (10 μM final concentration) + ZnOAc2 (25 μM final concentration) solution was added to the cultures. After incubation, cultures were washed twice with HBSS supplemented with 0.5% BSA and total RNA was isolated. A549 human lung cancer cells (1 x 10^5 cells per T-25 flask in 7 mL complete RPMI 1640 medium) were seeded 8 days prior to treatment of non-cycling plateau phase cultures with drug. At 4 hours prior to RNA isolation, PCI-5002 (10 μM final concentration) + ZnOAc2 (25 μM final concentration) solution was added to the cultures. After incubation, cultures were washed twice with HBSS supplemented with 0.5% BSA and total RNA was isolated.
 
 
Make groups for comparisons
(2 groups will be compared at a time)
Select GSMs and click on "Add groups"
Enter the group name here:


Select expression type
Transcripts profile based on;
A. Differential status (Up/Down regulation)
B. Absolute calls (Transcribed/Not-detected)
 
Filter results by number of probes